Despite improvements in cancer survival, cancer therapy–related cardiovascular toxicity has
risen to become a prominent clinical challenge. This has led to the growth of the burgeoning …

Although myocarditis and pericarditis were not observed as adverse events in coronavirus
disease 2019 (COVID-19) vaccine trials, there have been numerous reports of suspected …

Immune checkpoint inhibitors (ICIs) have changed how we think about tumor management.
Combinations of anti-programmed death ligand-1 (PD-L1) immunotherapy have become the …

Background Myocarditis is a dreaded and unpredictable complication of immune checkpoint
inhibitors (ICI). We sought to determine whether routinely measured biomarkers could be …

Abstract Purpose of Review Immune checkpoint inhibitors (ICIs) have improved the field of
cancer, especially in patients with advanced malignancies. Nevertheless, cardiovascular …

Simple Summary Myocarditis is an infrequent but highly hazardous complication of the
cancer therapy of immune checkpoint inhibitors (ICIs). The study of the pathophysiology of …

Cancer mortality has improved due to earlier detection via screening, as well as due to novel
cancer therapies such as tyrosine kinase inhibitors and immune checkpoint inhibitions …

Myocarditis has emerged as an immune-related adverse event of immune checkpoint
inhibitor (ICI) cancer therapy associated with significant mortality. To ensure patients …

Immune checkpoint inhibitors, introduced in recent years, have revolutionized the treatment
of many cancers. However, the toxicity associated with this therapy may cause severe …

Cancer is the leading cause of death globally and there is a worldwide cancer epidemic.
Immunotherapy has emerged as a promising anticancer therapy. In particular, oncolytic …